



PATENT
Attorney Docket No. WYE-076

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Aston <i>et al.</i>	CONFIRMATION NO.:	8289
SERIAL NO.:	10/706,791	GROUP NO.:	1634
FILING DATE:	November 12, 2003	EXAMINER:	Lu, Frank Wei Min
TITLE:	Methods and Compositions for Treating Neurological Disorders		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the non-U.S. patent documents and non-patent publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) above but before the mailing date of any of a **final action** under 37 C.F.R. 1.113, a **notice of allowance** under 37 C.F.R. 1.311, or an action that otherwise closes prosecution in the application, and
 - the requisite Statement is below, **OR**
 - the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein; or

Supplemental Information Disclosure Statement


Serial No.: 10/706,791

Page 2 of 2

(3) after the period defined in (2) above but before the payment of the issue fee, AND
 the requisite Statement is below, AND
 the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

Respectfully submitted,




Brian A. Fairchild
Attorney for Applicants
Kirkpatrick & Lockhart Nicholson
Graham LLP
State Street Financial Center
One Lincoln Street
Boston, Massachusetts 02111-2950

Date: September 15, 2006
Reg. No. 48,6450

Tel. No.: (617) 261-3169
Fax No.: (617) 261-3175

BOS-1007046 v1



Express Mail Mailing Label No.: EV832483006US

SHEET 1 OF 1

FORM PTO - 1449 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: WYE-076 APPLICANT(S): Aston <i>et al.</i> SERIAL NO.: 10/706,791 FILING DATE: November 12, 2003 GROUP NO.: 1634					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	C1	Mackay <i>et al.</i> , "Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors <i>in Vitro</i> and <i>in Vivo</i> ," <i>J. Cereb. Blood Flow Metab.</i> , 23(10):1160-1167 (2003).							
	C2	Schreiber, "Small molecules: the missing link in central dogma," <i>Nature Chemical Biology</i> , 1(2):64-66 (2005).							
EXAMINER				DATE CONSIDERED					